CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 27 enrolled
Drug / intervention
Lactobacillus crispatus CTV-05 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03151967
NCT03151967Phase 3Completed
CompareCT.gov

Lactobacillus Probiotic for Prevention of UTI

University of Washington·interventional·Posted May 12, 2017·Updated Mar 1, 2023

In Brief

A Phase 3 clinical trial evaluating Lactobacillus crispatus CTV-05 and Placebo for Urinary Tract Infections (UTI's). Completed, enrolled 27 participants across 2 sites.

Detailed Summary

The purpose of this research is to see whether LACTIN-V (Lactobacillus crispatus CTV-05) is an effective method of preventing recurrent urinary tract infections (UTI's) and to learn the side effects of LACTIN-V. LACTIN-V is a vaginal applicator that contains Lactobacillus crispatus, an organism found naturally in the vaginas of healthy women. Lactobacillus bacteria are thought to help prevent other bacteria such as E. coli from causing UTI's. This is a double blind study comparing active product to a placebo (inactive vaginal applicator without any medicine).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsUrinary Tract Infections (UTI's)
CountriesUnited States
CollaboratorsNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Timeline

Phase 3CompletedFinished
20162017201820192020202120222023202420252026
First PostedMay 12, 2017
Enrollment StartSep 1, 2015
Primary CompletionApr 5, 2017
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 9.1 years ago

Interventions

Lactobacillus crispatus CTV-05drug

vaginal applicator with medium containing drug

Placebodrug

vaginal applicator with medium containing no drug